Lhermitte, Ludovic

Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency

Boutboul, D., Kuehn, H. S., Van de Wyngaert, Z., Niemela, J. E., Callebaut, I., Stoddard, J., Lenoir, C., Barlogis, V., Farnarier, C., Vely, F., et al. (2018) · Journal of Clinical Investigation

Immunodeficiency and Autoimmune DisordersT-cell and B-cell Immunology

Cited by 169

Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS

Lemal, R., Fouquet, G., Terriou, L., Vaes, M., Livideanu, C. B., Frenzel, L., Barete, S., Canioni, D., Lhermitte, L., Rossignol, J., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice

Mast cells and histamineFood Allergy and Anaphylaxis Research

Cited by 70

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Guilhot, F., Rigal-Huguet, F., Guilhot, J., Guerci-Bresler, A.-P., Maloisel, F., Rea, D., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 30